Aspirin

(redirected from Acetylsalicylate)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.

Aspirin

Australian Stock Price Riskless Indexed Notes. Zero-coupon four-year bonds repayable at face value plus the percentage increase by which the Australian stock index of all ordinaries (common stocks) rises above a predefined level during the given period.

Aspirin

Australian Stock Price Riskless Index Note. A debt security with no coupon with a return based on the return of a benchmark stock index. Unlike most zero-coupon bonds, an Aspirin is issued at face value; however, like others, it is redeemed at face value at maturity, which is four years after issue. The return (or the equivalent of a coupon) on an Aspirin is the fact that the bondholder receives a percentage of the return on the Australian all-ordinaries stock index provided it is over a certain amount. For example, if the limit is 5% and the return is 9% over the four years of the Aspirin, the bondholder receives a return of 4%. However, if the return on the all-ordinaries index falls below the limit, the bondholder receives no return. Aspirins allow investors to participate in the stock market without assuming all of the risk involved.
Mentioned in ?
References in periodicals archive ?
Drugs Frequency Benzodiazepines 155 Tricyclic antidepressants Amitriptyline 46 Maprotiline 14 Clomipramine 12 Nortriptyline 7 Doxepin 3 Dosulepin 1 Imipramine 1 Amoxapin 1 Other antidepressants Fluoxetine 8 Mianserin 4 Viloxazine 1 Fuvoxamine 3 Neuroleptic agents Cyamemazine 18 Hydroxyzine 16 Metoclopramide 11 Alimemazine 10 Acepromazine 5 Thioridazine 1 Carbamates Meprobamate (a) 37 Febarbamate 3 Hypnotic drugs Zopiclone 7 Phenobarbital 5 Zolpidem 4 Drugs Frequency Analgesic drugs Dextropropoxyphene 12 Acetaminophen 4 Acetylsalicylate 3 Meperidine 1 Codeine 4 Chlormezanone 2 [beta]-Adrenergic blocking agents Acebutolol 5 Propranolol 1 Cold-cough remedies Ephedrine 7 Phenylpropanolamine 4 Fenspiride 2 Quinine 1 Anti-[H.
Nouveau Marche: NICOX) announces that a grant has been awarded by the National Cancer Institute of the NIH to scientists at the American Health Foundation in Valhalla, New York to study the effect of several of NicOx's patented nitric oxide-releasing compounds, including NCX-4016 and other derivatives of acetylsalicylates and NSAIDs, on the chemoprevention of colon cancer.